{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:02:10Z","timestamp":1791302530203,"version":"4.1.0"},"publisher-location":"Berlin, Heidelberg","reference-count":33,"publisher":"Springer Berlin Heidelberg","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/82_2026_357","type":"book-chapter","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:49:11Z","timestamp":1791301751000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Resolution Failure in Multiple Sclerosis: Linking Lipid Mediators to Neuroinflammation and Disease Progression"],"prefix":"10.1007","author":[{"given":"Valerio","family":"Chiurchi\u00f9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"357_CR1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","volume":"22","author":"KE Attfield","year":"2022","unstructured":"Attfield KE, Jensen LT, Kaufmann M, Friese MA, Fugger L (2022) The immunology of multiple sclerosis. Nat Rev Immunol 22:734\u2013750","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"357_CR2","doi-asserted-by":"crossref","first-page":"e533","DOI":"10.1212\/WNL.0000000000207459","volume":"101","author":"JY Broos","year":"2023","unstructured":"Broos JY, Loonstra FC, de Ruiter LRJ, Gouda M, Fung WH, Schoonheim MM, Heijink M, Strijbis EMM, Teunissen C, Killestein J, de Vries HE, Giera M, Uitdehaag BMJ, Kooij G (2023) Association of arachidonic acid-derived lipid mediators with disease severity in patients with relapsing and progressive multiple sclerosis. Neurology 101(5):e533\u2013e545","journal-title":"Neurology"},{"issue":"1","key":"357_CR3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12974-023-02981-w","volume":"21","author":"JY Broos","year":"2024","unstructured":"Broos JY, van der Burgt RTM, Konings J, Rijnsburger M, Werz O, de Vries HE, Giera M, Kooij G (2024) Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: fueling or dampening disease progression? J Neuroinflammation 21(1):21","journal-title":"J Neuroinflammation"},{"key":"357_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/1352458517737389","volume":"24","author":"K Castro","year":"2018","unstructured":"Castro K, Casaccia P (2018) Epigenetic modifications in brain and immune cells of multiple sclerosis patients. Mult Scler J 24:69\u201374","journal-title":"Mult Scler J"},{"key":"357_CR5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.cell.2023.03.008","volume":"186","author":"M Charabati","year":"2023","unstructured":"Charabati M, Wheeler MA, Weiner HL, Quintana FJ (2023) Multiple sclerosis: neuroimmune crosstalk and therapeutic targeting. Cell 186:1309\u20131327","journal-title":"Cell"},{"issue":"22","key":"357_CR6","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.2174\/1568026614666141203143801","volume":"14","author":"V Chiurchi\u00f9","year":"2014","unstructured":"Chiurchi\u00f9 V (2014) Novel targets in multiple sclerosis: to oxidative stress and beyond. Curr Top Med Chem 14(22):2590\u20132599","journal-title":"Curr Top Med Chem"},{"issue":"2","key":"357_CR7","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.neuron.2018.09.022","volume":"100","author":"S Da Mesquita","year":"2018","unstructured":"Da Mesquita S, Fu Z, Kipnis J (2018) The meningeal lymphatic system: a new player in neurophysiology. Neuron 100(2):375\u2013388","journal-title":"Neuron"},{"key":"357_CR8","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241306684","volume":"17","author":"A Dal-Bianco","year":"2024","unstructured":"Dal-Bianco A, Oh J, Sati P, Absinta M (2024) Chronic active lesions in multiple sclerosis: classification, terminology, and clinical significance. Ther Adv Neurol Disord 17:17562864241306684","journal-title":"Ther Adv Neurol Disord"},{"key":"357_CR9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.coi.2017.10.007","volume":"50","author":"J Dalli","year":"2018","unstructured":"Dalli J, Serhan CN (2018) Immunoresolvents signaling molecules at intersection between the brain and immune system. Curr Opin Immunol 50:48\u201354","journal-title":"Curr Opin Immunol"},{"key":"357_CR10","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nri3871","volume":"15","author":"CA Dendrou","year":"2015","unstructured":"Dendrou CA, Fugger L, Friese MA (2015) Immunopathology of multiple sclerosis. Nat Rev Immunol 15:545\u2013558","journal-title":"Nat Rev Immunol"},{"issue":"9","key":"357_CR11","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109201","volume":"35","author":"C Derada Troletti","year":"2021","unstructured":"Derada Troletti C, Enzmann G, Chiurchi\u00f9 V, Kamermans A, Tietz SM, Norris PC, Jahromi NH, Leuti A, van der Pol SMA, Schouten M, Serhan CN, de Vries HE, Engelhardt B, Kooij G (2021) Pro-resolving lipid mediator lipoxin A4 attenuates neuro-inflammation by modulating T cell responses and modifies the spinal cord lipidome. Cell Rep 35(9):109201","journal-title":"Cell Rep"},{"key":"357_CR12","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/ana.20736","volume":"59","author":"R Dutta","year":"2006","unstructured":"Dutta R et al (2006) Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients. Ann Neurol 59:478\u2013489","journal-title":"Ann Neurol"},{"issue":"1","key":"357_CR13","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00401-025-02878-3","volume":"149","author":"CE Hansen","year":"2025","unstructured":"Hansen CE, Konings J, Toth G, Chornyi S, Karsten M, van Het Hof B, van der Pol SMA, Beekhuis-Hoekstra SD, Kok N, Fung WK, Dijksman NS, Baron W, Witte ME, Lanekoff I, de Vries HE, Kooij G (2025) Spatial mapping of the AA-PGE2-EP axis in multiple sclerosis lesions. Acta Neuropathol 149(1):39","journal-title":"Acta Neuropathol"},{"issue":"3","key":"357_CR14","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nic.2024.03.004","volume":"34","author":"CC Hemond","year":"2024","unstructured":"Hemond CC, Gait\u00e1n MI, Absinta M, Reich DS (2024) New imaging markers in multiple sclerosis and related disorders: smoldering inflammation and the central vein sign. Neuroimaging Clin N Am 34(3):359\u2013373","journal-title":"Neuroimaging Clin N Am"},{"issue":"5_suppl","key":"357_CR15","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/13524585241292974","volume":"30","author":"A Hochstetler","year":"2024","unstructured":"Hochstetler A, Lehtinen MK (2024) Choroid plexus as a mediator of CNS inflammation in multiple sclerosis. Mult Scler 30(5_suppl):19\u201323","journal-title":"Mult Scler"},{"issue":"8","key":"357_CR16","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.3324\/haematol.2019.219519","volume":"105","author":"G Kooij","year":"2020","unstructured":"Kooij G, Troletti CD, Leuti A, Norris PC, Riley I, Albanese M, Ruggieri S, Libreros S, van der Pol SMA, van Het Hof B, Schell Y, Guerrera G, Buttari F, Mercuri NB, Centonze D, Gasperini C, Battistini L, de Vries HE, Serhan CN, Chiurchi\u00f9 V (2020) Specialized pro-resolving lipid mediators are differentially altered in peripheral blood of patients with multiple sclerosis and attenuate monocyte and blood-brain barrier dysfunction. Haematologica 105(8):2056\u20132070","journal-title":"Haematologica"},{"key":"357_CR17","doi-asserted-by":"crossref","first-page":"e1562","DOI":"10.1212\/WNL.98.18_supplement.1562","volume":"98","author":"IA Lie","year":"2022","unstructured":"Lie IA et al (2022) Relationship between white matter lesions and gray matter atrophy in multiple sclerosis. Neurology 98:e1562\u2013e1573","journal-title":"Neurology"},{"key":"357_CR18","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S1474-4422(20)30140-X","volume":"19","author":"C Lubetzki","year":"2020","unstructured":"Lubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B (2020) Remyelination in multiple sclerosis: from basic science to clinical translation. Lancet Neurol 19:678\u2013688","journal-title":"Lancet Neurol"},{"issue":"8","key":"357_CR19","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/s41582-023-00838-7","volume":"19","author":"R Magliozzi","year":"2023","unstructured":"Magliozzi R, Howell OW, Calabrese M, Reynolds R (2023) Meningeal inflammation as a driver of cortical grey matter pathology and clinical progression in multiple sclerosis. Nat Rev Neurol 19(8):461\u2013476","journal-title":"Nat Rev Neurol"},{"key":"357_CR20","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD (2021) Diagnosis and treatment of multiple sclerosis. JAMA 325:765","journal-title":"JAMA"},{"issue":"6","key":"357_CR21","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1001\/jamaneurol.2025.0495","volume":"82","author":"J M\u00fcller","year":"2025","unstructured":"M\u00fcller J et al (2025) Standardized definition of progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis. JAMA Neurol 82(6):614\u2013625","journal-title":"JAMA Neurol"},{"issue":"52","key":"357_CR22","doi-asserted-by":"crossref","first-page":"30697","DOI":"10.1074\/jbc.M115.679068","volume":"290","author":"LM Poisson","year":"2015","unstructured":"Poisson LM, Suhail H, Singh J, Datta I, Denic A, Labuzek K, Hoda MN, Shankar A, Kumar A, Cerghet M, Elias S, Mohney RP, Rodriguez M, Rattan R, Mangalam AK, Giri S (2015) Untargeted plasma metabolomics identifies endogenous metabolite with drug-like properties in chronic animal model of multiple sclerosis. J Biol Chem 290(52):30697\u201330712","journal-title":"J Biol Chem"},{"issue":"2","key":"357_CR23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055859","volume":"8","author":"H Pr\u00fcss","year":"2013","unstructured":"Pr\u00fcss H, Rosche B, Sullivan AB, Brommer B, Wengert O, Gronert K, Schwab JM (2013) Proresolution lipid mediators in multiple sclerosis \u2013 differential, disease severity-dependent synthesis \u2013 a clinical pilot trial. PLoS One 8(2):e55859","journal-title":"PLoS One"},{"issue":"1","key":"357_CR24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-neuro-113023-103045","volume":"47","author":"AFM Salvador","year":"2024","unstructured":"Salvador AFM, Abduljawad N, Kipnis J (2024) Meningeal lymphatics in central nervous system diseases. Annu Rev Neurosci 47(1):323\u2013344","journal-title":"Annu Rev Neurosci"},{"issue":"1","key":"357_CR25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12974-022-02386-1","volume":"19","author":"A S\u00e1nchez-Fern\u00e1ndez","year":"2022","unstructured":"S\u00e1nchez-Fern\u00e1ndez A, Zandee S, Mastrogiovanni M, Charabati M, Rubbo H, Prat A, L\u00f3pez-Vales R (2022) Administration of Maresin-1 ameliorates the physiopathology of experimental autoimmune encephalomyelitis. J Neuroinflammation 19(1):27","journal-title":"J Neuroinflammation"},{"issue":"1","key":"357_CR26","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/embj.201386609","volume":"33","author":"M Schwartz","year":"2014","unstructured":"Schwartz M, Baruch K (2014) The resolution of neuroinflammation in neurodegeneration: leukocyte recruitment via the choroid plexus. EMBO J 33(1):7\u201322","journal-title":"EMBO J"},{"issue":"2","key":"357_CR27","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintor\u00e9 M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"key":"357_CR28","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2021.673549","volume":"15","author":"M Tiberi","year":"2021","unstructured":"Tiberi M, Chiurchi\u00f9 V (2021) Specialized pro-resolving lipid mediators and glial cells: emerging candidates for brain homeostasis and repair. Front Cell Neurosci 15:673549","journal-title":"Front Cell Neurosci"},{"issue":"14","key":"357_CR29","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler 26(14):1816\u20131821","journal-title":"Mult Scler"},{"issue":"7","key":"357_CR30","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41583-024-00823-z","volume":"25","author":"MS Woo","year":"2024","unstructured":"Woo MS, Engler JB, Friese MA (2024) The neuropathobiology of multiple sclerosis. Nat Rev Neurosci 25(7):493\u2013513","journal-title":"Nat Rev Neurosci"},{"issue":"2","key":"357_CR31","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12016-020-08796-4","volume":"60","author":"I Zahoor","year":"2021","unstructured":"Zahoor I, Giri S (2021) Specialized pro-resolving lipid mediators: emerging therapeutic candidates for multiple sclerosis. Clin Rev Allergy Immunol 60(2):147\u2013163","journal-title":"Clin Rev Allergy Immunol"},{"key":"357_CR32","doi-asserted-by":"crossref","unstructured":"Zahoor I, Waters J, Ata N, Datta I, Pedersen TL, Cerghet M, Poisson L, Markovic-Plese S, Rattan R, Taha AY, Newman JW, Giri S (2024) Blood-based targeted metabolipidomics reveals altered omega fatty acid-derived lipid mediators in relapsing-remitting multiple sclerosis patients. bioRxiv [Preprint]. 2024.01.04.574253","DOI":"10.1101\/2024.01.04.574253"},{"issue":"3","key":"357_CR33","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2025.108226","volume":"301","author":"I Zahoor","year":"2025","unstructured":"Zahoor I, Nematullah M, Ahmed ME, Fatma M, Sajad M, Ayasolla K, Cerghet M, Palaniyandi S, Ceci V, Carrera G, Buttari F, Centonze D, Mao-Draayer Y, Rattan R, Chiurchi\u00f9 V, Giri S (2025) Maresin-1 promotes neuroprotection and modulates metabolic and inflammatory responses in disease-associated cell types in preclinical models of multiple sclerosis. J Biol Chem 301(3):108226","journal-title":"J Biol Chem"}],"container-title":["Current Topics in Microbiology and Immunology"],"original-title":[],"link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/82_2026_357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:49:16Z","timestamp":1791301756000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/82_2026_357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":33,"URL":"https:\/\/doi.org\/10.1007\/82_2026_357","relation":{},"ISSN":["0070-217X","2196-9965"],"issn-type":[{"value":"0070-217X","type":"print"},{"value":"2196-9965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"7 October 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"The author(s) has no competing interests to declare that are relevant to the content of this manuscript.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author(s) declares that this manuscript does not include primary research with human participants.The author(s) declares that this manuscript does not include primary studies involving animals.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}